As such, we have identified potential TGF-β inhibitors for this purpose that are currently in active and interventional clinical trials for the treatment of cardiotoxicity or heart disease (including heart failure, cardiovascular disease, ischemic heart disease, coronary heart disease, arrhythmia, etc.)from the Clinicaltrials.gov database, summarized in Table 1. This evidence concerns the gene TGFB1 and cardiovascular disorder.